FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to recombinant anti-tumour proteins, and can be used in medicine in the treatment of tumour. Disclosed are a protein consisting of a spacer peptide and a mutant of recombinant immunomodulating protein Ganoderma lucidum (mutant rLZ-8), as well as agents for recombinant production thereof, agents containing same and a method for use in anticancer therapy.
EFFECT: invention provides tumour treatment by means of cytotoxic activity due to use of the offered protein possessing high ability to kill tumour cells.
13 cl, 25 dwg, 10 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODY AND USE THEREOF | 2021 |
|
RU2839153C2 |
| FUSION PROTEIN OF GPC3 TARGETING ANTIBODY AND INTERFERON α AND USE THEREOF | 2022 |
|
RU2836245C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| PHARMACEUTICAL COMPOSITION POSSESSING ANTITUMOUR EFFECT, AND METHOD FOR REDUCING PD-L1 INHIBITING EFFECT ON HUMAN T-CELLS | 2016 |
|
RU2688692C2 |
| ANTIBODIES AGAINST THE PROGRAMMED DEATH LIGAND (PD-L1) AND APPLICATION THEREOF | 2019 |
|
RU2761638C1 |
| BISPECIFIC ANTIBODIES AND THEIR APPLICATIONS | 2022 |
|
RU2821577C2 |
| AFFINITY-MATURED MICA ANTIBODY AND USE THEREOF | 2024 |
|
RU2838565C1 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| PEPTIDES CAPABLE OF REACTIVATING P53 MUTANTS | 2014 |
|
RU2693487C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
